C
Christopher Stroh
Researcher at Merck KGaA
Publications - 23
Citations - 3848
Christopher Stroh is an academic researcher from Merck KGaA. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 11 publications receiving 3527 citations.
Papers
More filters
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
Kenneth J. O'Byrne,Ulrich Gatzemeier,Igor Bondarenko,Carlos H. Barrios,Corinna Eschbach,Uwe M. Martens,Yevhen Hotko,Cornelius Kortsik,Luis Paz-Ares,José Rodrigues Pereira,Joachim von Pawel,Rodryg Ramlau,Jae Kyung Roh,Chih Teng Yu,Christopher Stroh,Ilhan Celik,Armin Schueler,Robert Pirker +17 more
TL;DR: The FLEX study as discussed by the authors showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival in the first-line treatment of EGFRexpressing, advanced non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
TL;DR: The prospects for selective MET inhibitors in the treatment of non-small cell lung cancer harboring MET exon 14 skipping are discussed and increasing evidence suggests that tumors carrying such mutations are sensitive to MET inhibition, raising the hope that selectiveMET inhibitors will provide patients with optimal anticancer activity with minimal toxicity.
Journal ArticleDOI
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
Florian Lordick,Yoon-Koo Kang,Pamela Salman,Sang Cheul Oh,György Bodoky,G. Kurteva,Constantin Volovat,Vladimir Moiseyenko,Akira Sawaki,Joon Oh Park,Vera Gorbunova,Heiko Goette,Helena Melezínková,Christopher Stroh,Markus Moehler +14 more
TL;DR: This analysis assessed treatment outcome according to tumor HER2 status (a pre-defined subgroup) and EGFR expression in EXPAND study pts, finding that pts with HER2 +ve tumors had a longer median overall survival.
Journal ArticleDOI
Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
TL;DR: Cetuximab activity in NSCLC patient-derived xenograft models was demonstrated clearly only in tumors that expressed high levels of EGFR, as defined by an IHC score of ≥200.